INMB Seeks Shareholder Nod for Stock Option Repricing

TL;DR

**INMB is repricing options to keep employees happy, but shareholders should scrutinize the dilution risk.**

AI Summary

Inmune Bio, Inc. (INMB) is holding a Special Meeting of Stockholders on November 18, 2025, to seek approval for the repricing of certain outstanding stock options under its 2017, 2019, and 2021 Stock Incentive Plans. This 'Option Repricing Proposal' is the primary agenda item, aiming to adjust the exercise price of existing options, likely to incentivize employees and executives given potential stock price declines. The company also seeks approval for an 'Adjournment Proposal,' allowing the meeting to be postponed if insufficient votes are received for the option repricing. As of the September 30, 2025 record date, 26,585,258 shares of common stock were issued and outstanding, each entitled to one vote. The Board of Directors recommends a 'FOR' vote on both proposals. This DEF 14A filing does not contain specific revenue or net income figures, nor does it detail the exact number of options to be repriced or the proposed new exercise prices, focusing solely on the procedural aspects of seeking stockholder approval for the repricing mechanism.

Why It Matters

This option repricing proposal is a critical move for INmune Bio to retain and motivate key talent, especially if the company's stock price has underperformed, rendering existing options 'underwater.' For investors, approving this could dilute future earnings per share or signal management's concern over employee retention, but rejecting it might lead to a brain drain. Competitively, other biotech firms often use similar mechanisms to keep their R&D teams engaged in a volatile market. The outcome will directly impact employee morale and the company's ability to execute its strategic pipeline.

Risk Assessment

Risk Level: medium — The risk level is medium because while the filing doesn't detail the extent of the repricing, option repricing typically dilutes shareholder value by effectively granting new, lower-priced options. The lack of specific numbers regarding the options to be repriced or the proposed new exercise prices in this DEF 14A means shareholders are voting on the principle without full financial context, which introduces uncertainty.

Analyst Insight

Investors should vote 'FOR' the Option Repricing Proposal only after carefully considering the potential dilution against the benefits of retaining key talent. Demand more transparency on the number of options and the proposed new strike prices before the November 18, 2025 meeting. If the company's performance has been poor, this could be a necessary evil to prevent a talent exodus.

Key Numbers

• 26,585,258 — Shares Outstanding (As of the September 30, 2025 record date, each share is entitled to one vote.)
• November 18, 2025 — Special Meeting Date (Date when stockholders will vote on the option repricing and adjournment proposals.)
• September 30, 2025 — Record Date (Date by which stockholders must own shares to vote at the Special Meeting.)

Key Players & Entities

• Inmune Bio, Inc. (company) — Registrant seeking proxy approval
• David Moss (person) — Chief Executive Officer and Director
• Securities and Exchange Commission (regulator) — Regulatory body for filing
• Nasdaq Capital Market (company) — Stock exchange where INMB is listed
• 2017 Stock Incentive Plan (other) — One of the plans under which options are being repriced
• 2019 Stock Incentive Plan (other) — One of the plans under which options are being repriced
• Second Amended and Restated 2021 Stock Incentive Plan (other) — One of the plans under which options are being repriced
• 26,585,258 (dollar_amount) — Shares of common stock issued and outstanding as of September 30, 2025
• November 18, 2025 (date) — Date of the Special Meeting of Stockholders
• September 30, 2025 (date) — Record date for the Special Meeting

FAQ

Industry Context

INmune Bio, Inc. operates in the biotechnology sector, focusing on developing therapies for cancer and inflammatory diseases. This sector is characterized by high research and development costs, long development cycles, and significant regulatory hurdles. Success often depends on clinical trial outcomes and the ability to secure funding for ongoing research and development.

Regulatory Implications

The company's operations are subject to stringent regulations by bodies like the FDA. Any missteps in clinical trials, manufacturing, or marketing can lead to significant delays, financial penalties, or product rejection. The approval of proposals related to equity compensation, like option repricing, also falls under SEC regulations and corporate governance standards.

What Investors Should Do

1. Review the Option Repricing Proposal carefully to understand its potential impact on dilution and executive compensation before voting.
2. Consider the rationale behind the Adjournment Proposal and its implications for the timing of key decisions.
3. Vote on the proposals by the deadline to ensure your voice is heard in the company's governance.

Key Dates

• 2025-11-18: Special Meeting of Stockholders — Stockholders will vote on the Option Repricing Proposal and the Adjournment Proposal.
• 2025-10-14: Mailing of Proxy Materials — Commencement of distribution of proxy statements and proxy cards to stockholders of record.
• 2025-09-30: Record Date — Determines which stockholders are entitled to vote at the Special Meeting.

Glossary

DEF 14A

A filing with the U.S. Securities and Exchange Commission (SEC) that must be filed by companies when they solicit proxies from shareholders for an annual or special meeting. (This document outlines the proposals to be voted on at the Special Meeting and provides relevant background information.)

Option Repricing Proposal

A proposal seeking stockholder approval to adjust the exercise price of certain outstanding stock options. (This is the primary agenda item for the Special Meeting, aimed at potentially reissuing options at a lower strike price.)

Adjournment Proposal

A proposal that allows the company to postpone or adjourn the meeting if necessary, for example, to solicit additional votes. (This proposal provides flexibility to the company to ensure quorum or achieve necessary approvals for other proposals.)

Stock Incentive Plans

Plans established by a company to grant equity-based compensation, such as stock options, to employees and executives. (The repricing of options under these plans (2017, 2019, and 2021) is the subject of the main proposal.)

Year-Over-Year Comparison

This DEF 14A filing focuses on the upcoming Special Meeting and proposals related to stock option repricing and adjournment. It does not contain comparative financial data from a previous year's filing, such as revenue growth or changes in net income. The primary focus is on corporate governance and equity incentive adjustments rather than a comprehensive financial review.

Filing Documents

• ea0259630-02.htm (DEF 14A) — 324KB
• tinmunebio_logo.jpg (GRAPHIC) — 85KB
• tproxy_001.jpg (GRAPHIC) — 988KB
• tproxy_002.jpg (GRAPHIC) — 817KB
• 0001213900-25-098715.txt ( ) — 2930KB

Security Ownership of Certain Beneficial Owners and Management

Security Ownership of Certain Beneficial Owners and Management   12 General Matters   13 i Table of Contents INmune Bio Inc. 225 NE Mizner Blvd., Suite 640 Boca Raton, FL 33432 PROXY STATEMENT FOR THE 2025 SPECIAL MEETING OF STOCKHOLDERS To Be Held on November 18, 2025 The Board of Directors of INmune Bio Inc. (the “Board of Directors,” “Board,” or “our Board”) is soliciting proxies from stockholders for its use at the 2025 special meeting of our stockholders (the “Special Meeting”), and at any continuation, postponement, or adjournment of that meeting. The Special Meeting is scheduled to be held on November 18, 2025, at 10:00 a.m., Eastern Time, in a virtual meeting format, which will be conducted via live webcast at  www.virtualshareholdermeeting.com / INMB2025SM . In this proxy statement, “we,” “our,” “us,” the “Company,” “INmune,” “INmune Bio,” and similar designations refer to INmune Bio Inc. The mailing address of our principal executive offices is INmune Bio Inc., 225 NE Mizner Blvd. Suite 640, Boca Raton FL 33432. Please see the “Information About the Special Meeting and Voting” section of this proxy statement for more details regarding the logistics of the virtual Special Meeting, including the ability of stockholders to submit questions during the Special Meeting, and technical details and support related to accessing the virtual platform. There is no physical location for the Special Meeting. You will not be able to attend the Special Meeting in person. All properly submitted proxies will be voted in accordance with the instructions contained in those proxies. If no instructions are specified, the proxies will be voted in accordance with the recommendation of the Board of Directors with respect to each of the matters se

View Full Filing

View this DEF 14A filing on SEC EDGAR